vidence from several large, randomized control trials has demonstrated that statins reduce coronary morbidity and mortality in patients with coronary artery disease. [1] [2] [3] The mechanisms underlying this protective action of statins may be related to their independent pleiotropic effects and the reduction of low-density lipoprotein cholesterol. Statins may, in fact, have anti-inflammatory effects, 4 improve endothelial function, and have direct protective effects on myocardial cells. 5 In addition, intensive lowering of low-density lipoprotein cholesterol with high-dose statin therapy provides favorable long-term clinical outcomes in patients with coronary artery disease.
Results
A flow diagram of this study is shown in Figure 1 . Serial followup OCT evaluations were performed in 50 patients (83.3%) at the 3 planned time intervals (post procedure and 3-and 12-month follow-ups; Figure 1 ). The main cause of patients lost to follow-up was refusal of the follow-up angiogram at the 3-and 12-month follow-ups. There were no statistically significant differences in clinical and angiographic characteristics between the atorvastatin-versus pravastatin-treated group ( Table 1) . The lipid profiles, high-sensitivity C-reactive protein level, white blood cell count, hemoglobin A1c level, fasting glucose level, and creatinine level at the index procedure and 12-month follow-up are shown in Table 2 . The lowdensity lipoprotein cholesterol level was significantly lower in the atorvastatin-treated group (68.7±24.6 versus 83.2±28.4 mg/dL in the pravastatin-treated group; P=0.04); the reduction of total cholesterol level was significantly greater in the atorvastatin-treated group (−50.0±41.8 versus −25.6±48.2 mg/dL in the pravastatin-treated group; P=0.04). There were no statistically significant differences in quantitative coronary angiographic analysis parameters between the 2 groups ( Table 3) .
The results of serial OCT analysis are shown in Table 4 . Postprocedural OCT variables were similar between the 2 groups. The percentage of uncovered struts at the 3-month follow-up was lower in the atorvastatin-treated group without statistical significance (7.4% [range, 4.3%-10.4%] versus 10.6% [range, 5.7%- 22 .6%] in the pravastatin-treated group; P=0.13). The 12-month follow-up OCT analysis showed that it was significantly lower in the atorvastatin-treated group (1.3% [range, 0.3%-3.8%] versus 2.5% [range, 0.9%-9.7%] in the pravastatin-treated group; P=0.01; Figure 2 ). The representative OCT images are shown in Figure 3 . The percentage Δ of uncovered struts from the 3-to 12-month follow-ups was −7.9±8.5% in atorvastatin-treated patients versus −9.3±12.5% in pravastatin-treated patients (P=0.67). The cross sections without uncovered struts and those with a ratio of uncovered/ total struts >0.3 were also significantly smaller in the atorvastatin-treated group (Table 4) . There was no statistically significant difference in the percentage Δ of uncovered struts from the 3-month to 12-month follow-ups between the 2 groups. The serial change in the uncovered struts among the statins, stents, and time interval are shown in Figure 4 .
The interobserver and intraobserver agreements on neointimal hyperplasia thickness were excellent (interobserver agreement: Interclass correlation coefficient (ICC), 0.91; 95% confidence interval, 0.88-0.93 and intraobserver agreement: ICC, 0.91; 95% confidence interval, 0.88-0.92). In addition, agreements on uncovered struts were good (interobserver and intraobserver: κ=0.86 and 0.87, respectively).
Discussion
This serial randomized OCT study suggested that high-dose statin therapy showed significantly better DES strut coverage than low-dose statin therapy at the 12-month follow-up. Therefore, high-dose statin therapy may be helpful to enhance the vascular healing process after DES implantation.
Previous autopsy studies reported that the most important histological risk factors for stent thrombosis were endothelial coverage and the ratio of uncovered/total strut after first-generation DES implantation. 6, 7 Therefore, delayed vascular healing and, subsequently, a larger number of remaining uncovered struts have been considered to be causes for late stent failures in DES-treated patients in real clinical practice. [12] [13] [14] In clinical practice, OCT is the requisite intravascular modality for evaluating the stent strut coverage with high resolution compared with angiography or intravascular ultrasound that cannot assess stent strut coverage because of its limited resolution. 8, 9 To obtain more favorable DES strut coverage, second-generation DESs with a thin stent thickness, more biocompatible polymer, and an adequate eluting dosage of drug have been developed; previous OCT studies have reported a significantly lower percentage of uncovered struts in everolimus-eluting stent-treated patients than in first-generation sirolimus-eluting stent-treated patients. 15, 16 However, there have been few investigations to assess the effect of statin treatment on vascular healing after DES implantation. The vascular healing process after bare-metal stent implantation is composed of thrombus formation, accumulation of inflammatory cells and smooth muscle cells, and re-endothelialization. 17 However, the predominant feature of vascular healing after DES implantation was delayed strut coverage because of persistent peristrut inflammation and impaired endothelialization. 6 Previous studies have reported that statin treatment might be associated not only with a lipid-lowering effect but also with pleiotropic effects (ie, improvement in endothelial function, reduction of inflammation, suppression of atherosclerotic plaque progression, and reduction of bare-metal stent in restenosis) in experimental and clinical investigations. 10,18-20 Wang et al 10 reported that atorvastatin pretreatment could enhance both neointimal coverage and re-endothelialization after first-generation sirolimus-eluting stent implantation in a porcine model, a process that may be mediated by the mobilization of endothelial progenitor cells and enhancement of the endothelial function. A recent randomized clinical OCT study showed that, compared with pravastatin treatment (n=20), rosuvastatin treatment (n=20) resulted in a lower frequency of uncovered struts after DES implantation. 20 In addition, statin therapy has been shown to inhibit platelet aggregation and release of platelet-derived mediators, 21, 22 as well as to reduce inflammatory responses of the vascular wall, 23, 24 and to improve coronary endothelial function, 25 all of which may contribute to the beneficial effect of statin therapy on proliferative responses after coronary stent implantation in humans. Furthermore, high-dose atorvastatin has been reported to exert stronger anti-inflammatory and platelet inhibitory effects than low-dose atorvastatin by reducing platelet activity and inflammatory chemokines. 26 
Clinical Implications
Considering the drawbacks of previous studies, the current investigation may be novel in 3 aspects. First, a malapposed strut immediately after stent implantation can be controlled by OCT-guided stent implantation, which may clearly prove the effect of statin. Second, 2 stents were randomly implanted, possibly minimizing the effect of the stent. Third, serial follow-up (3 months and 12 months) was performed to evaluate the stent healing process according to the statin dose. 11, 20 Previous studies have reported a higher percentage of uncovered struts in patients with late/very late DES thrombosis. [12] [13] [14] However, the lower percentage of strut coverage at the 12-month follow-up was observed even in low-dose statintreated patients in this study. The main reasons for the different percentage of uncovered struts between the previous studies [12] [13] [14] and this study were as follows. Compared with angiographyguided DES implantation in the previous studies, [12] [13] [14] OCTguided DES implantation, which could significantly reduce the uncovered stent struts at the follow-up, 27 was performed in this study. In addition, 12-month follow-up OCT evaluation was performed in clinically stable and asymptomatic situations, not at the time of onset of DES thrombosis in this study.
Endothelialization and healthy neointima formation over stent struts have been crucial processes to prevent stent thrombosis. Therefore, assessment of the degree of strut coverage is clinically important to determine the duration of dual antiplatelet therapy after DES implantation. This study can be used to compare the effects of different statin doses on the in vivo serial healing process (3 and 12 months) after DES implantation. The use of high-dose statins for a prolonged Values are presented as n (%) or mean±SD. 
Limitations
There are several limitations in this study. First, the application of current findings should be applicable to patients with simple uncomplicated lesions, such as those explored in this study. Complex lesions and high-risk patients were excluded from this study. Second, although the underlying arterial wall plaque characteristics could affect stent healing after DES implantation, preintervention OCT examinations were not performed in this study. Third, stent strut coverage cannot be clearly evaluated in lesions with a thin neointima >10 to 15 µm in thickness because axial resolution of OCT is 10 to 15 µm. 8 Fourth, the sample size for stent strut comparison between high-dose versus low-dose statin therapy might not be appropriate, and the number of patients was small to assess the relationship with clinical outcomes. In addition, because the difference in the percentage of uncovered struts was mainly driven by the difference in lesions with first-generation sirolimus-eluting stents, which is not currently available, the findings in this study should be validated with a larger number of patients treated with 
Conclusions
This is a serial randomized OCT study to demonstrate that high-dose statin treatment significantly reduced the percentage of uncovered struts after DES implantation at the 12-month follow-up. Representative optical coherence tomographic images on the atorvastatin (top) and pravastatin (bottom) groups. The uncovered struts were observed at 3 months, but they were covered at 12 months in the atorvastatin group (top). The uncovered struts were frequently observed at 3 months and persisted at 12 months in the pravastatin group (bottom). 
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